Science Policy For All

Because science policy affects everyone.

Posts Tagged ‘eucalyptus

Science Policy Around the Web – August 29, 2014

leave a comment »

By: Jennifer L. Plank, Ph.D.

photo credit: itmpa via photopin cc


Brazil Considers Transgenic Trees – In September, a public hearing in Brazil will be focused on commercialization of transgenic Eucalyptus trees that have the potential to produce 20 percent more wood. So far, genetically modified trees from major commercialized species have been planted on a large scale suggesting that this hearing will have global implications. Despite potential environmental advantages, the GMO trees have received much opposition. One cause of opposition is the length of time the trees will be alive compared to other GMO crops such as soy and corn. Meanwhile, in the United States, another company, who has generated freeze-resistant eucalyptus, is anxiously awaiting the ruling in Brazil.  (Heidi Ledford)


Infectious Disease and Public Health

AIDS Progress in South Africa is in Peril – Until recently, the AIDS epidemic in South Africa has kept undertakers in business. However, within the past 6 years, there has been a dramatic increase in the ability to treat and prevent the spread of HIV. There has been a drastic increase in the number of clinics and health care practitioners prescribing antiretroviral drugs. In fact, each month 100,000 new patients begin a regiment of anti-retroviral drugs, more than any other country in the world. Additionally, maternal to fetal transmission has decreased 90 percent. All of this suggests an astounding success in South Africa. Much of this success can be attributed to the US program PEPFAR, the President’s Emergency Plan for AIDS Relief. Unfortunately, with the PEPFAR pipeline drying up, the programs in South Africa are in danger of not being able to continue their work. (Donald G. McNeil Jr.)



Ebola Vaccine to be tested in humans at NIH Clinical Center this fall – In collaboration with GlaxoSmithKline, NIH researches will begin clinical trials of an Ebola vaccine. The trial will test the safety of the vaccine and its ability to induce an immune response. The initial trial will include approximately 20 participants. Similar trials will be conducted in other countries. (Brady Dennis)


Have an interesting science policy link?  Share it in the comments!


Written by sciencepolicyforall

August 29, 2014 at 3:21 pm